Predicted protein targets (top 3)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TACR2 | P21452 | 17/20 | 0.63 |
| ▸ | PRCP | P42785 | 3/20 | 0.40 |
| ▸ | KCNH2 | Q12809 | 2/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4260405 | 1.00 | TACR2 (0.63) | TACR2PRCPKCNH2 | |
| Hydrochloric Acid SCHEMBL4259647 | 0.99 | TACR2 (0.62) | TACR2PRCPKCNH2 | |
| SCHEMBL5798623 | 0.94 | TACR2 (0.59) | TACR2PRCPKCNH2 | |
| SCHEMBL4261931 | 0.94 | TACR2 (0.59) | TACR2PRCPKCNH2 | |
| Hydrochloric Acid SCHEMBL6002305 | 0.94 | TACR2 (0.58) | TACR2PRCPKCNH2 | |
| Hydrochloric Acid SCHEMBL4263009 | 0.94 | TACR2 (0.58) | TACR2PRCPKCNH2 | |
| SCHEMBL5800692 | 0.90 | TACR2 (0.68) | TACR2 | |
| SCHEMBL4257606 | 0.90 | TACR2 (0.68) | TACR2 | |
| SCHEMBL5799585 | 0.90 | TACR2 (0.51) | TACR2 | |
| SCHEMBL4255121 | 0.90 | TACR2 (0.51) | TACR2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2007043939-A1 | NOVEL CRYSTALLINE FORM OF 3,5-DIBROMO-N- [(2S)-2-(-4-FLUOROPHENYL)-4-(3-MORPHOLIN-4-YLAZETIDIN-1-YL)BUTYL] -N-METHYLBENZAMIDE, MODIFICATION A | ASTRAZENECA AB (SE) | 2007-04-19 | — | — | WO | claimed |
| WO-2007043939-A1 | NOVEL CRYSTALLINE FORM OF 3,5-DIBROMO-N- [(2S)-2-(-4-FLUOROPHENYL)-4-(3-MORPHOLIN-4-YLAZETIDIN-1-YL)BUTYL] -N-METHYLBENZAMIDE, MODIFICATION A | ASTRAZENECA AB (SE) | 2007-04-19 | — | — | WO | disclosed |
| WO-2007043938-A1 | NOVEL CRYSTALLINE FORM OF 3,5-DIBROMO-N- [ (2S) -2- (-4- FLUOROPHENYL) -4- (3-MORPHOLIN-4-YLAZTIDIN-l-YL) BUTYL] -N METHYLBENZAMIDE, MODIFICATION B | ASTRAZENECA AB (SE) | 2007-04-19 | — | — | WO | disclosed |
| WO-2006062478-A1 | NOVEL TREATMENT OF GASTROINTESTINAL DISORDERS | ASTRAZENECA AB (SE) | 2006-06-15 | — | — | WO | disclosed |